Recent Quotes (30 days)

You have no recent quotes
chg | %

BELLUS Health Inc  

(Public, TSE:BLU)   Watch this stock  
Find more results for BLU
0.365
+0.005 (1.39%)
Jun 23 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.36 - 0.37
52 week 0.21 - 0.55
Open 0.36
Vol / Avg. 37,200.00/125,797.00
Mkt cap 21.69M
P/E     -
Div/yield     -
EPS -0.01
Shares 66.87M
Beta 2.19
Inst. own     -
Aug 8, 2017
Q2 2017 BELLUS Health Inc Earnings Release (Estimated) Add to calendar
May 12, 2017
BELLUS Health Inc Annual Shareholders Meeting (Estimated)
May 9, 2017
Q1 2017 BELLUS Health Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 12711.11% -117.70%
Operating margin -8977.78% -110.78%
EBITD margin - -110.78%
Return on average assets 42.43% -18.12%
Return on average equity 47.80% -24.95%
Employees 9 -
CDP Score - -

Address

275 Armand-Frappier Blvd
LAVAL, QC H7V 4A7
Canada
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)

Website links

Description

BELLUS Health Inc. is a drug development company focused on rare diseases. The business activities of the Company are development of the Company's core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. The Company operates in the business segment of development of drugs for health solutions. It is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. Its pipeline of rare disease projects includes KIACTA in Phase III for Amyloid A (AA) amyloidosis; KIACTA for sarcoidosis; clinical stage Shigamab for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS), and a research-stage project for amyloid light-chain (AL) amyloidosis. It is partnered with global private equity firm Auven Therapeutics for the development of KIACTA.